Cohort profile: The Chikwawa lung health cohort; a population-based observational non-communicable respiratory disease study of adults in Malawi.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
05
2020
accepted:
28
10
2020
entrez:
12
11
2020
pubmed:
13
11
2020
medline:
2
1
2021
Statut:
epublish
Résumé
The aim of this article is to provide a detailed description of the Chikwawa lung health cohort which was established in rural Malawi to prospectively determine the prevalence and causes of lung disease amongst the general population of adults living in a low-income rural setting in Sub-Saharan Africa. A total of 1481 participants were randomly identified and recruited in 2014 for the baseline study. We collected data on demographic, socio-economic status, respiratory symptoms and potentially relevant exposures such as smoking, household fuels, environmental exposures, occupational history/exposures, dietary intake, healthcare utilization, cost (medication, outpatient visits and inpatient admissions) and productivity losses. Spirometry was performed to assess lung function. At baseline, 56.9% of the participants were female, mean age was 43.8 (SD:17.8) and mean body mass index (BMI) was 21.6 Kg/m2 (SD: 3.46). The cohort has reported the prevalence of chronic respiratory symptoms (13.6%, 95% confidence interval [CI], 11.9-15.4), spirometric obstruction (8.7%, 95% CI, 7.0-10.7), and spirometric restriction (34.8%, 95% CI, 31.7-38.0). Additionally, an annual decline in forced expiratory volume in one second [FEV1] of 30.9mL/year (95% CI: 21.6 to 40.1) and forced vital capacity [FVC] by 38.3 mL/year (95% CI: 28.5 to 48.1) has been reported. The ongoing phases of follow-up will determine the annual rate of decline in lung function as measured through spirometry and the development of airflow obstruction and restriction, and relate these to morbidity, mortality and economic cost of airflow obstruction and restriction. Population-based mathematical models will be developed driven by the empirical data from the cohort and national population data for Malawi to assess the effects of interventions and programmes to address the lung burden in Malawi. The present follow-up study started in 2019.
Identifiants
pubmed: 33180873
doi: 10.1371/journal.pone.0242226
pii: PONE-D-20-12808
pmc: PMC7660567
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0242226Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K006533/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L002515/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R011192/1
Pays : United Kingdom
Organisme : Department of Health
ID : 16/136/35
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared no competing interests.
Références
Environ Health Perspect. 2002 Jan;110(1):109-14
pubmed: 11781172
Thorax. 2020 Mar;75(3):220-226
pubmed: 32079666
Int J Tuberc Lung Dis. 2016 Jan;20(1):136-41
pubmed: 26688540
Int J Tuberc Lung Dis. 2013 May;17(5):583-9
pubmed: 23394105
Lancet Glob Health. 2017 Jan;5(1):e20-e21
pubmed: 27866775
J Glob Health. 2019 Jun;9(1):010434
pubmed: 31217961
Lancet Respir Med. 2017 Sep;5(9):691-706
pubmed: 28822787
Thorax. 2019 Nov;74(11):1070-1077
pubmed: 31467192
Int J Epidemiol. 2018 Dec 1;47(6):1736-1736k
pubmed: 29800224
Lancet. 2007 Dec 8;370(9603):1929-38
pubmed: 18063029
Postgrad Med J. 2011 Oct;87(1032):724-33
pubmed: 21954034
Clin Transl Sci. 2011 Jun;4(3):225-6
pubmed: 21707955
Eur J Epidemiol. 2015 Mar;30(3):163-88
pubmed: 25527371
Proc R Soc Med. 1952 Sep;45(9):577-84
pubmed: 13003946
Ann Am Thorac Soc. 2017 May;14(5):714-721
pubmed: 28244800
Epidemiol Rev. 2001;23(2):268-87
pubmed: 12192737
Thorax. 2014 Sep;69(9):805-10
pubmed: 24646659
Allergy. 2009 Jul;64(7):1061-7
pubmed: 19210360
Lancet. 2017 Jan 14;389(10065):167-175
pubmed: 27939058
BMC Int Health Hum Rights. 2010 Nov 10;10:27
pubmed: 21062503
Am J Respir Crit Care Med. 2016 Jul 1;194(1):67-76
pubmed: 26788760
Bull World Health Organ. 2019 May 01;97(5):318-327
pubmed: 31551628
Br Med J. 1960 Dec 3;2(5213):1665-6
pubmed: 13688719
Int J Epidemiol. 2017 Feb 1;46(1):23
pubmed: 27378796
Am J Respir Crit Care Med. 2011 Feb 15;183(4):455-61
pubmed: 20870755
Eur Respir J. 2015 May;45(5):1239-47
pubmed: 25837037
Am J Respir Crit Care Med. 2010 Sep 1;182(5):693-718
pubmed: 20802169
N Engl J Med. 2015 Jul 9;373(2):111-22
pubmed: 26154786
Am J Respir Crit Care Med. 1999 Jan;159(1):179-87
pubmed: 9872837
Eur Respir J. 2005 Jul;26(1):153-61
pubmed: 15994402
Eur Respir J. 2012 Jun;39(6):1343-53
pubmed: 22183479
Int J Gen Med. 2018 Jun 28;11:255-264
pubmed: 29988742
Thorax. 2020 Mar;75(3):269-278
pubmed: 32102951
Am J Respir Crit Care Med. 2019 Mar 1;199(5):613-621
pubmed: 30141966
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
Am J Respir Crit Care Med. 2016 Jan 1;193(1):23-30
pubmed: 26351837
PLoS One. 2017 Dec 7;12(12):e0188437
pubmed: 29216193
Malawi Med J. 2006 Sep;18(3):134-46
pubmed: 27529007
COPD. 2005 Jun;2(2):277-83
pubmed: 17136954
Lancet. 2018 May 19;391(10134):2047-2058
pubmed: 29627161